

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)

Meeting – May 14, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
 - A. April 9, 2014 DUR Minutes – Vote
 - B. April 9, 2014 DUR Recommendation Memorandum

Items to be presented by Dr. Muchmore, Chairman:

- 4. Action Item – Vote to Change Meeting Time and Location – See Appendix B**

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 5. Update of Medication Coverage Authorization Unit/
SoonerPsych Program Update – See Appendix C**
 - A. Medication Coverage Activity for April 2014
 - B. Pharmacy Help Desk Activity for April 2014
 - C. SoonerPsych Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 6. Action Item – Vote to Prior Authorize Ophthalmic Anti-Inflammatories – See Appendix D**
 - A. Introduction
 - B. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 7. Action Item – Vote to Prior Authorize Lorzone™ (Chlorzoxazone) – See Appendix E**
 - A. COP Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

- 8. Action Item – Vote to Prior Authorize Farxiga™ (Dapagliflozin) and
Invokana™ (Canagliflozin) – See Appendix F**
 - A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 9. Action Item – Vote to Prior Authorize Luzu® (Luliconazole) – See Appendix G**
 - A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 10. Action Item – Vote to Prior Authorize Zorvolex™ (Diclofenac) and Tivorbex™ (Indomethacin) – See Appendix H**
A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 11. Annual Review of Anticonvulsant Medications and 30-Day Notice to Prior Authorize Trokendi XR™ (Topiramate ER), Aptiom® (Elis carbazepine Acetate), and Qudexy™ XR (Topiramate ER) – See Appendix I**
A. Current Prior Authorization Criteria
B. Utilization of Anticonvulsants
C. Prior Authorization of Anticonvulsants
D. Market News and Updates
E. COP Recommendations
F. Utilization Details
G. Product Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 12. 30-Day Notice to Prior Authorize Sovaldi™ (Sofosbuvir), Olysio™ (Simeprevir), Victrelis® (Boceprevir), and Incivek® (Telaprevir) – See Appendix J**
A. Introduction
B. Utilization Details Sovaldi™ and Olysio™
C. Market News and Updates
D. Medication Summaries
E. COP Recommendations
F. Utilization Details
G. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 13. FDA and DEA Updates – See Appendix K**

14. Future Business

- A. Annual Reviews
B. New Product Reviews

15. Adjournment